Start the conversation
It was the first stock we recommended on the very first day that we published Private Briefing.
And this "Baby Biotech" subsequently soared as much as 214%.
The stock has sold off a bit since then - but held strong when other biotechs swooned late last year.
This is premium content for Private Briefing subscribers only.